New developments of brain imaging for Parkinson's Disease and related disorders

Movement Disorders

Volumn 21, Issue 12, 2006, Pages 2035-2041

  Piccini, Paola ^a   Brooks, David J ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Functional imaging; Movement disorders; Parkinson's disease

Indexed keywords

CARBON 11; DOPAMINE; DOPAMINE 2 RECEPTOR; GLYCOPROTEIN P; IODINE 123; LEVODOPA; MULTIDRUG RESISTANCE PROTEIN 1; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; RACLOPRIDE;

BASAL GANGLION; BLOOD BRAIN BARRIER; BRAIN DEGENERATION; BRAIN METABOLISM; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; DISEASE ASSOCIATION; DISEASE COURSE; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; ECHOGRAPHY; HUMAN; MEDICAL ASSESSMENT; NEUROCHEMISTRY; NEUROIMAGING; NEUROTRANSMITTER RELEASE; NIGRONEOSTRIATAL SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; RECEPTOR BINDING; REVIEW; SENSITIVITY AND SPECIFICITY; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TASK PERFORMANCE; TREATMENT OUTCOME; UNIFIED PARKINSON DISEASE RATING SCALE;

BLOOD-BRAIN BARRIER; BRAIN MAPPING; DIAGNOSTIC IMAGING; HUMANS; MICROGLIA; PARKINSON DISEASE; PARKINSONIAN DISORDERS;

EID: 33846433117     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20845     Document Type: Review

References (42)

1. Berg D, Siefker C, Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol 2001;248:684-689.
2. Berg D, Roggendorf W, Schroder U, et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 2002; 59:999-1005.
3. Berg D, Merz B, Reiners K, Naumann M, Becker G. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov Disord 2005;20:383-385.
4. Berg D, Becker G, Zeiler B, et al. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 1999;53: 1026-1031.
5. Berg D, Siefker C, Ruprecht-Dorfler P, Becker G. Relationship of substantia nigra echogenicity and motor function in elderly subjects. Neurology 2001;56:13-17.
6. Ruprecht-Dorfler P, Berg D, Tucha O, et al. Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson's disease. Neuroimage 2003;18:416-422.
7. Walter U, Klein C, Hilker R, Benecke R, Pramstaller PP, Dressler D. Brain parenchyma sonography detects preclinical parkinsonism. Mov Disord 2004;19:1445-1449.
8. Walter U, Niehaus L, Probst T, Benecke R, Meyer BU, Dressler D. Brain parenchyma sonography discriminates Parkinson's disease and atypical parkinsonian syndromes. Neurology 2003;60:74-77.
9. Kortekaas R, Leenders KL, van Oostrom JC, Vaalburg W, Bart J, Willemsen AT, Hendrikse NH. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 2005;57:176-179.
10. Behnke S, Berg D, Naumann M, Becker G. Differentiation of Parkinson's disease and atypical parkinsonian syndromes by transcranial ultrasound. J Neurol Neurosurg Psychiatry 2005;76:423-425.
11. Hutchinson M, Raff U. Parkinson's disease: a novel MRI method for determining structural changes in the substantia nigra. J Neurol Neurosurg Psychiatry 1999;67:815-818.
12. Hu MT, White SJ, Herlihy AH, Chaudhuri KR, Hajnal JV, Brooks DJ. A comparison of (18)F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson's disease. Neurology 2001;56:1195-1200.
13. Hutchinson M, Raff U, Lebedev S. MRI correlates of pathology in parkinsonism: segmented inversion recovery ratio imaging (SIR-RIM). Neuroimage 2003;20:1899-1902.
14. Schrag A, Good CD, Miszkiel K, et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000;54:697-702.
15. Seppi K, Schocke MF, Esterhammer R, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 2003;60:922-927.
16. Brooks DJ, Turjanski N, Sawle GV, Playford ED, Lees AJ. PET studies on the integrity of the pre- and post-synaptic dopaminergic system in Tourette's syndrome. Adv Neurol 1992;58:227-232.
17. Seppi K, Schocke MF, Donnemiller E, et al. Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease. Mov Disord 2004; 19:1438-1445.
18. Breier A, Su TP, Saunders RC, et al. Schizophrenia is associated with elevated amphetamine induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997;94:2569-2574.
19. Chugani DC, Ackermann RF, Phelps ME. In vivo [3H]spiperone binding: evidence for accumulation in corpus striatum by agonist-mediated receptor internalization. J Cereb Blood Flow Metab 1988;8:291-303.
20. Muriel MP, Bernard V, Levey AI, et al. Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease. Ann Neurol 1999;46:103-111.
21. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 2000;20:423-451.
22. Schlaepfer TE, Pearlson GD, Wong DF, et al. PET study of competition between intravenous cocaine and [C-11]raclopride at dopamine receptors in human subjects. Arch J Psychiatry 1997; 154:1209-1213.
23. Volkow ND, Wang GJ, Fowler JS, et al. Imaging endogenous dopamine competition with [11C]raclopride in the human brain. Synapse 1994;15:255-262.
24. Carson RE, Breier A, deBartolomeis A, et al. Quantification of amphetamine-induced changes in [C-11]raclopride binding with continuous infusion. J Cereb Blood Flow Metab 1998;17:437-447.
25. Ginovart N, Farde L, Haldin C, Swahn CG. Changes in striatal D2-density following chronic treatment with amphetamine assessed with PET in nonhuman primates. Synapse 1999;31:154-162.
26. Piccini P, Pavese N, Brooks DJ. An in vivo study of striatal and cortical endogenous dopamine release following pharmacological challenges in Parkinson's disease. Ann Neurol 2003;53:647-653.
27. de la Fuente-Fernandez R, Lu JQ, Sossi V, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol 2001;49:298-303.
28. de la Fuente-Femandez R, Sossi V, Huang Z, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004;127(Pt. 12):2747-2754.
29. Strafella AP, Paus T, Barrett J, Dagher A. Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. J Neurosci 2001;21:RC157.
30. Strafella AP, Paus T, Fraraccio M, Dagher A. Striatal dopamine release induced by repetitive transcranial magnetic stimulation of the human motor cortex. Brain 2003;126:2609-2615.
31. Koepp MJ, Gunn RN, Lawrence AD, et al. Evidence for striatal dopamin release during a video game. Nature 1998;393:266-268.
32. Goerendt IK, Messa C, Lawrence AD, et al. Dopamine release during sequential finger movements in Parkinson's disease: a PET study. Brain 2003;126:312-325.
33. Sawamoto N, Hotton GR, Pavese N, Piccini P, Brooks DJ. Frontal endogenous dopamine release detected with 11C-Raclopride during a visual search task in healthy subjects and Parkinson's disease patients. Neurology 2005;64(Suppl. 1):A274.
34. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996;19:312-318.
35. Tatton WG, Chalmers-Redman R, Brown D, Tatton N. Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann Neurol 2003;53(Suppl. 3):S61-S70.
36. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988;38:1285-1291.
37. Wu DC, Jackson-Lewis V, Vila M, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002;22:1763-1771.
38. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, Torizuka T. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 2005;57:168-175.
39. Gerhard A, Pavese N, Hotton GR, et al. Microglial activation in parkinson's disease: its longitudinal course and correlation with clinical parameters - an 11C(R)-PK11195 PET study. Neurology 2004;62(Suppl. 5):A432.
40. Drozdzik M, Bialecka M, Mysliwiec K, Honczarenko K, Stankiewicz J, Sych Z. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 2003;13: 259-263.
41. Stoessl AJ, McGeer PL. Hot spots: can positron emission tomography offer insights into the pathogenesis of PD? Ann Neurol 2005;57:161-162.
42. Berg D, Siefker C, Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol 2001;248:684-689.